Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "Eloxatine 50 mg" (19)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Oxaliplatin (L01XA03) 19 products
WHO-DDD
DrugBank.ca
IP
Oxaliplatin Zentiva 50
mg/10 ml
76.67
99.80
10 %
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Helvepharm AG
A / SL / SG
FB
G
IP
Oxaliplatin Zentiva 100
mg/20 ml
152.76
182.55
10 %
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Helvepharm AG
A / SL / SG
FB
G
IP
Oxaliplatin Zentiva 200
mg/40 ml
262.75
302.15
10 %
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Helvepharm AG
A / SL / SG
FB
G
IP
CM
Helveplatin 50 mg/10 ml
PR
PR
k.A.
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Helvepharm AG
A
FB
G
IP
CM
Helveplatin 100 mg/20 ml
PR
PR
k.A.
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Helvepharm AG
A
FB
G
IP
CM
Helveplatin 200 mg/40 ml
PR
PR
k.A.
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Helvepharm AG
A
FB
G
IP
Eloxatine 50 mg/10 ml
Durchstechflasche(n)
84.32
107.65
10 %
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Sanofi-Aventis
(Suisse) SA
A / SL / SO
FB
G
IP
Eloxatine 100 mg/20 ml
Durchstechflasche(n)
168.03
198.20
10 %
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Sanofi-Aventis
(Suisse) SA
A / SL / SO
FB
G
IP
Eloxatine 200 mg/40 ml
Durchstechflasche(n)
289.02
329.15
10 %
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Sanofi-Aventis
(Suisse) SA
A / SL / SO
FB
G
IP
Oxaliplatin Accord 50
mg/10 ml
76.66
99.80
10 %
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Accord Healthcare AG
●
A / SL / SG
FB
G
IP
Oxaliplatin Accord 100
mg/20 ml
152.76
182.55
10 %
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Accord Healthcare AG
A / SL / SG
FB
G
IP
Oxaliplatin Accord 200
mg/40 ml
262.75
302.15
10 %
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Accord Healthcare AG
A / SL / SG
FB
G
IP
Oxaliplatin Sandoz 50
mg/10 ml
76.67
99.80
10 %
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
IP
Oxaliplatin Sandoz 100
mg/20 ml
152.76
182.55
10 %
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
IP
Oxaliplatin Sandoz 200
mg/40 ml
262.75
302.15
10 %
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Sandoz
Pharmaceuticals AG
A / SL / SG
FB
G
IP
Oxaliplatin-Teva liquid 50
mg/10 ml
Durchstechflasche(n)
76.67
99.80
10 %
Concentrate for infusion: Oxaliplatinum 50mg / 10ml
Teva Pharma AG
A / SL / SG
FB
G
IP
Oxaliplatin-Teva liquid 100
mg/20 ml
Durchstechflasche(n)
152.76
182.55
10 %
Concentrate for infusion: Oxaliplatinum 100mg / 20ml
Teva Pharma AG
●
A / SL / SG
FB
G
IP
Oxaliplatin-Teva liquid 200
mg/40 ml
Durchstechflasche(n)
262.75
302.15
10 %
Concentrate for infusion: Oxaliplatinum 200mg / 40ml
Teva Pharma AG
●
A / SL / SG
FB
G
IP
Oxaliplatin Sandoz 250
mg/50 ml
PR
PR
k.A.
Concentrate for infusion: Oxaliplatinum 250mg / 50ml
Sandoz
Pharmaceuticals AG
A
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
